Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
Zacks.com on MSN5h
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for InvestorsThe latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...
If we earn tomorrow’s dividend and then get assigned at expiration on October 25, we will earn $1.65 per share on $52.95 per ...
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
Investor's Business Daily on MSN11h
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
The Centers for Medicare & Medicaid Services (CMS) has added several changes to the Medicare price negotiation process ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback